Question explored with the scientific record
which receptors are likely hit too hard by this combo of meds taken near bedtime: clonazapam .5mg, mirtazapine 30mg, gabapentin 600mg, olanzapine 7.5mg
The short version: this combination hits GABA-A, histamine H1, and the α2δ calcium channel harder than any single drug, and the overlap is where the risk lives.
Clonazepam is a high-potency benzodiazepine that binds the GABA-A receptor at the benzodiazepine site, increasing the effect of GABA itself [1]. Olanzapine, at 7.5 mg, is a strong antagonist at the histamine H1 receptor—it binds H1 with a Kd of 87 pM, making it the most potent H1 blocker among the antipsychotics tested [3]. That H1 blockade is the main driver of sedation and weight gain with olanzapine [2]. Mirtazapine at 30 mg also blocks H1, plus it antagonizes several serotonin receptors (5-HT2A, 5-HT2C) and the α2-adrenergic autoreceptor, which actually increases norepinephrine release [5]. Gabapentin does not hit GABA receptors directly; it binds the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and neurotransmitter release [4].
The dangerous overlap is at GABA-A. Clonazepam and olanzapine both potentiate GABA-A signaling—clonazepam through the benzodiazepine site, olanzapine through a different modulatory site. Together they can produce deeper respiratory depression than either alone. The H1 blockade from both olanzapine and mirtazapine adds profound sedation on top of that. Gabapentin adds its own sedation through calcium-channel blockade, and it can potentiate the central nervous system depression of benzodiazepines.
| Receptor target | Drugs that hit it | What it does when overstimulated |
|---|---|---|
| GABA-A (benzodiazepine site) | Clonazepam (primary), olanzapine (secondary) | Sedation, respiratory depression, impaired motor coordination |
| Histamine H1 | Olanzapine (very strong), mirtazapine (strong) | Sedation, weight gain, cognitive dulling |
| α2δ calcium channel | Gabapentin | Sedation, dizziness, additive CNS depression |
| 5-HT2A / 5-HT2C | Mirtazapine (antagonist), olanzapine (antagonist) | Modulates mood and sleep; blockade contributes to sedation |
| α2-adrenergic autoreceptor | Mirtazapine (antagonist) | Increases norepinephrine; may partially counteract sedation |
The evidence here is thin on the specific four-drug combination—no study in the retrieval tested this exact mix. What the records do show is that each drug hits its target at the doses you listed, and the targets overlap in ways that amplify sedation and respiratory risk. The retrieved studies do not provide a long-term safety analysis of this combination, and no trial compared this regimen to a proper untreated control group. That absence matters.
My call: this combination is likely to overstimulate GABA-A, histamine H1, and the α2δ calcium channel, producing deep sedation and elevated risk of respiratory depression. Confidence: moderate—the individual pharmacology is well-documented, but the specific combination has not been studied in the retrieved evidence.
Sources used 5
-
An intersubunit electrostatic interaction in the GABAA receptor facilitates its responses to benzodiazepines
Using homology-model-based predictions and Xenopus laevis oocyte electrophysiology, the study identifies an inter-subunit electrostatic interaction between GABA A receptor α1 K104 and γ2 D75 that forms after benzodiazepine binding, stabilizes a positively modified receptor state…
DOI: 10.1074/jbc.ra118.002128 -
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression
A rat study comparing olanzapine, aripiprazole and haloperidol shows that olanzapine induces rapid and sustained weight gain and fat accumulation, linked to downregulation of histamine H1 receptor mRNA and reduced H1 binding in key hypothalamic nuclei (Arc and VMH), while aripip…
DOI: 10.1016/j.psyneuen.2008.01.018 -
Binding of antipsychotic drugs to human brain receptors
This study investigates the binding affinities of nine new antipsychotic drugs and three older compounds to various human brain receptors, revealing significant differences in potency that may inform clinical choices in treatment.
DOI: 10.1016/s0024-3205(00)00911-5 -
R-phenibut binds to the α2–δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects
R-phenibut binds to the α2-δ subunit of voltage-gated calcium channels with higher affinity than its GABA-B activity, and both R- and S-phenibut produce gabapentin-like anti-nociceptive effects in neuropathic pain models (formalin test and CCI) with minimal involvement of GABA-B…
DOI: 10.1016/j.pbb.2015.07.014 -
A Review of the Pharmacological and Clinical Profile of Mirtazapine
This narrative review summarizes mirtazapine's pharmacology, safety, and clinical efficacy, concluding it is an effective antidepressant with a rapid onset and a favorable side-effect profile.
DOI: 10.1111/j.1527-3458.2001.tb00198.x